i An update to this article is included at the end

Annals of Oncology 28 (Supplement 4): iv72–iv83, 2017

doi:10.1093/annonc/mdx220

CLINICAL PRACTICE GUIDELINES

Cervical cancer: ESMO Clinical Practice Guidelines for

diagnosis, treatment and follow-up†

C. Marth1, F. Landoni2, S. Mahner3, M. McCormack4, A. Gonzalez-Martin5 & N. Colombo2, on behalf of the

ESMO Guidelines Committee*
1
Department of Obstetrics and Gynecology, Medical University Innsbruck, Innsbruck, Austria; 2Department of Gynecologic Oncology, European Institute of
Oncology, Milan, Italy; 3Department of Gynecology and Obstetrics, University of Munich, Munich, Germany; 4Department of Oncology, University College Hospital,
London, UK; 5Medical Oncology Department, MD Anderson Cancer Center, Madrid, Spain

*Correspondence to: ESMO Guidelines Committee, ESMO Head Office, Via L. Taddei 4, CH-6962 Viganello-Lugano, Switzerland. E-mail: clinicalguidelines@esmo.org
†
Approved by the ESMO Guidelines Committee: January 2008, last update May 2017. This publication supersedes the previously published version—Ann Oncol 2012;
23(Suppl 7): vii27–vii32.

Incidence and epidemiology 5 more oncogenic HPV viruses (HPV 31, 33, 45, 52 and 58) in
Cervical cancer is the second most commonly diagnosed cancer addition to the types already included in 4vHPV, which cause an
and the third leading cause of cancer death among females in less additional 15% of HPV-related cancers in women and 4% of
developed countries. There were an estimated 527 600 new cer- those in men [4]. Both the 2vHPV and 4vHPV have significant
vical cancer cases and 265 700 deaths worldwide in 2012 [1]. cross-protective activity against other oncogenic viruses. All three
Nearly 90% of cervical cancer deaths occurred in developing parts are efficacious against related infection and cervical, vaginal, vul-
of the world. The large geographic variation in cervical cancer var and anal dysplasia [5–7].
rates reflects differences in the availability of screening (which Post-licensure reports from countries with established HPV
allows for the detection and removal of precancerous lesions) and vaccination programs indicate that HPV vaccination has a bene-
in human papillomavirus (HPV) infection prevalence. ficial effect at the population level as early as 3 years after the
However, cervical cancer still represents a major public health introduction of an HPV vaccination programme, including de-
problem even in developed countries: more than 58 000 new cases creases in the incidence of high-grade cervical abnormalities, the
of cervical cancer are diagnosed and  24 000 patients die in prevalence of vaccine HPV types and the incidence of genital
Europe every year [2]. Five-year relative survival for European warts [8, 9]. Prophylactic administration of HPV vaccine can ef-
women diagnosed with cervical cancer in 2000–2007 was 62%, fectively prevent infection and disease associated with the vaccine
ranging from 57% in Eastern Europe to 67% in Northern HPV types. The effect of vaccination on the burden of cancer re-
Europe. Survival was particularly low (< 55%) in Bulgaria, Latvia mains to be determined but, according to surrogate markers, it is
and Poland and highest in Norway (71%) [3]. Survival decreased expected to prevent > 70% of cervical cancers.
with advancing age at diagnosis, from 81% for 15–44-year olds to For many years, the Papanicolaou (Pap) test has been the
34% for women  75 years. Survival increased significantly from standard method for cervical cancer screening, reducing the inci-
61% in 1999–2001 to 65% in 2005–2007. FIGO stage is one of the dence by 60%–90% and the death rate by 90%. However, the
most important prognostic factors. limitations of this cytology-based test are the sensitivity ( 50%)
The most significant cause of cervical cancer is persistent papil- and significant proportion of inadequate specimens. More re-
lomavirus infection. HPV is detected in 99% of cervical tumours, cently, an HPV test has been introduced as a screening tool as
particularly the oncogenic subtypes such as HPV 16 and 18. HPV deoxyribonucleic acid (DNA) is present in almost all cer-
To date, three HPV vaccines are licensed and available: the bi- vical cancers and it has demonstrated higher sensitivity for high-
valent HPV virus-like particle vaccine (2vHPV), the quadrivalent grade cervical intraepithelial neoplasia (CIN2þ) than that
HPV virus-like particle vaccine (4vHPV) and nine-valent HPV achieved by cytology in several studies. A pooled analysis of four
virus-like particle vaccine (9vHPV). All 3 vaccines provide pro- randomised controlled trials of HPV-based cervical screening
tection against HPV 16 and 18. 4vHPV also includes HPV 6 and versus conventional cytology showed that HPV-based cervical
11 which cause 90% of genital warts. Furthermore, 9vHPV covers screening provides 60%–70% greater protection against invasive

C The Author 2017. Published by Oxford University Press on behalf of the European Society for Medical Oncology.
V
All rights reserved. For Permissions, please email: journals.permissions@oup.com.
Annals of Oncology Clinical Practice Guidelines
cancer compared with cytology-based screening [10]. Findings Table 1. WHO histological classification of tumours of the uterine cervix
support HPV-based screening with triage at prolonged inter-
Epithelial tumours
vals, starting at age 30 years. Especially in a vaccinated popula-
1. Squamous tumours and precursors
tion when dysplastic lesions will be less frequent, screening
Squamous cell carcinoma, not otherwise specified 8070/3
with Pap tests will be more difficult. Pap cytology has signifi-
Keratinising 8071/3
cant limitations. It is based on the subjective interpretation of Non-keratinising 8072/3
morphological alterations present in cervical samples that must Basaloid 8083/3
be collected with proper attention to sampling cells of the Verrucous 8051/3
transformation zone. Also, the highly repetitive nature of the Warty 8051/3
work of screening many smears leads to fatigue, which invari- Papillary 8052/3
ably causes errors in interpretation. Lymphoepithelioma-like 8082/3
Therefore, primary prevention of cervical cancer is now pos- Squamotransitional 8120/3
sible via immunisation with highly efficacious HPV vaccines [II, Early invasive (microinvasive) squamous cell carcinoma 8076/3
A] and secondary prevention has gained impetus with the advent Squamous intraepithelial neoplasia
of sensitive HPV DNA testing to improve traditional Pap cy- Cervical intraepithelial neoplasia (CIN) 3/ 8077/2
tology screening programmes [II, A]. squamous cell carcinoma in situ 8070/2
Benign squamous cell lesions
Condyloma acuminatum
Squamous papilloma 8052/0
Diagnosis and pathology/molecular biology Fibroepithelial polyp

Abnormal cervical cytology or a positive high-risk HPV test 2. Glandular tumours and precursors
Adenocarcinoma 8140/3
should lead to colposcopy and biopsy or excisional procedures
Mucinous adenocarcinoma 8480/3
such as loop electrosurgical excision and conisation. Early cer-
Endocervical 8482/3
vical cancer is often asymptomatic, while locally advanced disease
Intestinal 8144/3
could cause symptoms including abnormal vaginal bleeding (also
Signet-ring cell 8490/3
after coitus), discharge, pelvic pain and dyspareunia. Gross ap- Minimal deviation 8480/3
pearance is variable. Carcinomas can be exophytic, growing out Villoglandular 8262/3
of the surface, or endophytic with stromal infiltration with min- Endometrioid adenocarcinoma 8380/3
imal surface growth. Some early cancers are not easily detected Clear cell adenocarcinoma 8310/3
and even deeply invasive tumours may be somewhat deceptive on Serous adenocarcinoma 8441/3
gross examination. If examination is difficult or there is uncer- Mesonephric adenocarcinoma 9110/3
tainty about vaginal/parametrial involvement, examination Early invasive adenocarcinoma 8140/3
should preferably be done under anaesthesia by an interdisciplin- Adenocarcinoma in situ 8140/2
ary team including a gynaecological oncologist and a radiation Glandular dysplasia
oncologist. Benign glandular lesions
The World Health Organization (WHO) recognises three cate- Müllerian papilloma
gories of epithelial tumours of the cervix: squamous, glandular Endocervical polyp
(adenocarcinoma) and other epithelial tumours including 3. Other epithelial tumours
adenosquamous carcinoma, neuroendocrine tumours and undif- Adenosquamous carcinoma 8560/3
ferentiated carcinoma (Table 1). Squamous cell carcinomas ac- Glassy cell carcinoma variant 8015/3
count for  70%–80% of cervical cancers and adenocarcinomas Adenoid cystic carcinoma 8200/3
for 20%–25%. Adenoid basal carcinoma 8098/3
Neuroendocrine tumours
Carcinoid 8240/3
Squamous cell carcinoma Atypical carcinoid 8249/3
Small cell carcinoma 8041/3
Squamous carcinomas are composed of cells that are recognisably
Large cell neuroendocrine carcinoma 8013/3
squamous but vary in either growth pattern or cytological Undifferentiated carcinoma 8020/3
morphology. Originally, they were graded using Broders’ grading
system; subsequently, they were classified into keratinising, non- Mesenchymal tumours and tumour-like conditions
keratinising and small-cell squamous carcinomas. In the more re- Mixed epithelial and mesenchymal tumours
cent WHO classification, the term small-cell carcinoma was Melanocytic tumours
Miscellaneous tumours
reserved for tumours of neuroendocrine type. Keratinising squa-
Lymphoid and haematopoetic tumours
mous cell carcinomas are characterised by the presence of keratin
Secondary tumours
pearls. Mitoses are not frequent. Non-keratinising squamous cell
carcinomas do not form keratin pearls by definition, but may Morphology code of the International Classification of Diseases for
show individual cell keratinisation. Clear-cell changes can be Oncology (ICD-O) {921} and the Systematized Nomenclature of
prominent in some tumours and should not be misinterpreted as Medicine (http://snomed.org).
clear-cell carcinoma. WHO, World Health Organization.

Volume 28 | Supplement 4 | August 2017 doi:10.1093/annonc/mdx220 | iv73

Clinical Practice Guidelines Annals of Oncology
Adenocarcinoma International Cancer Control (UICC) TNM staging classifications
(8th edition) shown in Table 2. Cervical cancer is the only gynaeco-
The arrangement of the invasive glands is highly variable and
logical cancer that is clinically staged based on tumour size, vaginal
some tumours are in part or extensively papillary. About 80% of
or parametrial involvement, bladder/rectum extension and distant
adenocarcinomas of the cervix are of endocervical or usual type;
metastases. It requires examination under anaesthesia, radiological
unlike normal endocervical mucinous epithelium, tumour cells
imaging such as chest X-ray and intravenous pyelogram. These
are not obviously mucinous and show a rather characteristic ap-
have been widely replaced by more timely diagnostic tools. Other
pearance having eosinophilic cytoplasm. The most common type
imaging studies are used routinely to more accurately define the
is the mucinous type which comprises endocervical, intestinal
extent of disease and to allow tailoring of treatment, but do not
and gastric subtypes. The great majority of endocervical-type
affect the clinical stage. Computed tomography (CT) can detect
adenocarcinomas are architecturally well differentiated, but they
pathological lymph nodes, while magnetic resonance imaging
are cytologically grade 2 or 3. Only a subset of papillary or villo-
(MRI) can determine tumour size, degree of stromal penetrations,
glandular adenocarcinoma is considered well differentiated for
parametrial involvement, vaginal extension and corpus extension
their good prognosis when in pure form; tumours with an under-
with high accuracy [14]. More recently, positron emission tomog-
lying component of conventional adenocarcinoma behave as
raphy (PET) has been seen to have the potential to accurately de-
adenocarcinomas of the usual type. Unlike cervical squamous cell
lineate the extent of disease, particularly in lymph nodes that are
carcinomas, differential diagnosis of early invasive adenocarcin-
not macroscopically enlarged and in distant sites, with high sensi-
oma from adenocarcinoma in situ showing somewhat complex
tivity and specificity. In early-stage disease, PET/CT has a sensitiv-
architecture can be difficult. In mucinous adenocarcinoma
ity of 53%–73% and specificity of 90%–97% for the detection of
mucin-rich cells predominate; some show gastric-type features
lymph node involvement, while in more advanced stages the sensi-
and some are of the minimal deviation type (or adenoma
tivity for detecting the involvement of para-aortic nodes increases
malignum). Rare tumours are mixed adenosquamous carcin-
to 75% with 95% specificity [15]. The need for pretreatment
omas and include the so-called glassy cell carcinoma. The other
surgical para-aortic lymph node assessment in locally advanced
rarer types of cervical adenocarcinoma include clear-cell carcin-
cervical cancer (LACC) is still a matter of debate [16].
oma and mesonephric adenocarcinoma.
Tumour risk assessment includes tumour size, stage, depth of tu-
mour invasion, lymph node status, lymphovascular space invasion
Other cervical carcinoma (LVSI) and histological subtype. Lymph node status and number of
Neuroendocrine tumours include carcinoids, atypical carcinoids lymph nodes involved are the most important prognostic factors.
and neuroendocrine carcinomas. Diagnosis is histological and In stages IB–IIA, the 5-year survival rates without lymph node me-
can be confirmed by neuroendocrine markers. tastasis and with lymph node metastasis are 88%–95% and 51%–
78%, respectively [17].
Controversy exists as to whether histological type is an inde-
Pathogenesis—molecular biology pendent prognostic factor for survival. Although some studies
HPV has been recognised as the most important aetiological fac- have shown no differences in survival between adenocarcinoma
tor in cervical cancer. HPV 16/18 account for at least two-thirds and squamous cell carcinoma, the majority have shown that
of cervical carcinomas in all continents; HPV 31, 33, 35, 45, 52 adenocarcinoma carries a worse prognosis with 10%–20% differ-
and 58 are the next most common types of cancers globally. ences in 5-year overall survival (OS) rates.
HPV vaccines have a great impact on cervical cancer and HPV- Cervical small-cell neuroendocrine carcinoma is a rare disease,
associated cancers in males and females, thus leading to an annual re- accounting for only up to 2% of all invasive cervical cancers but
duction of 90% of cervical cancer, 85% of vaginal cancer HPV correl- has a particular propensity to spread distantly, which is similar to
ates, 87% of vulvar cancer HPV correlates, 92% of anal cancer HPV small-cell carcinoma of the lung. As a result, patients can present
correlates and 85% of penile cancer HPV correlates [11–13]. with systemic symptoms such as weight loss. In addition, patients
Squamous cell carcinomas and their precursor, intraepithelial may present with a paraneoplastic syndrome such as the syn-
squamous lesions, are related to HPV infection in almost all cases drome of inappropriate antidiuretic hormone secretion
and the presence of HPV 16 DNA is associated with poor prognosis. (SIADH), Cushing syndrome, hypercalcaemia or a neurological
Adenocarcinomas encompass a heterogeneous group of tumours. disorder. The most commonly involved organs include the liver,
Endocervical adenocarcinoma of usual type and its precursor, the adrenals, bone, bone marrow and the brain.
adenocarcinoma in situ, have been shown to be positive for HPV in
nearly 90% and 100% of cases, respectively. HPV 18 is more com-
mon in adenocarcinomas and adenosquamous carcinomas than in
Management of local/locoregional disease
squamous cell carcinomas. Unlike endocervical adenocarcinoma of
usual type, the other rarer types including clear-cell and mesoneph- (Figure 1)
ric adenocarcinoma seem to be unrelated to HPV.
Primary treatment

Surgery. Surgical therapy in cervical cancer is adapted to the stage

Staging and risk assessment of disease according to FIGO and TNM classification (Table 2).
Cervical tumours are staged using the Féderation Internationale Microinvasive cervical cancer (stage IA1) without LVSI can be
de Gynécologie et d’Obstétrique (FIGO) and the Union for managed with conisation or simple trachelectomy to preserve

iv74 | Marth et al. Volume 28 | Supplement 4 | August 2017

Annals of Oncology Clinical Practice Guidelines
Table 2. The staging of cervical tumours is by the Féderation Internationale de Gynécologie et d’Obstétrique (FIGO) and TNM classification (Union for
International Cancer Control) [61]
TNM clinical classification

TNM categories FIGO stages Definition

T – Primary Tumour
TX Primary tumour cannot be assessed
T0 No evidence of primary tumour
Tis Carcinoma in situ (preinvasive carcinoma)
T1 I Tumour confined to the cervixa
T1ab,c IA Invasive carcinoma diagnosed only by microscopy. Stromal invasion with a maximal depth of
5.0 mm measured from the base of the epithelium and a horizontal spread of 7.0 mm or lessd
T1a1 IA1 Measured stromal invasion 3.0 mm or less in depth and 7.0 mm or less in horizontal spread
T1a2 IA2 Measured stromal invasion more than 3.0 mm and not more than 5.0 mm with a horizontal
spread of 7.0 mm or lessd
T1b IB Clinically visible lesion confined to the cervix or microscopic lesion greater than T1a/IA2
T1b1 IB1 Clinically visible lesion 4.0 cm or less in greatest dimension
T1b2 IB2 Clinically visible lesion more than 4.0 cm in greatest dimension
T2 II Tumour invades beyond uterus but not to pelvic wall or to lower third of vagina
T2a IIA Tumour without parametrial invasion
T2a1 IIA1 Clinically visible lesion 4.0 cm or less in greatest dimension
T2a2 IIA2 Clinically visible lesion more than 4.0 cm in greatest dimension
T2b IIB Tumour with parametrial invasion
T3 III Tumour involves lower third of vagina, or extends to pelvic wall, or causes hydronephrosis or
non-functioning kidney
T3a IIIA Tumour involves lower third of vagina
T3b IIIB Tumour extends to pelvic wall, or causes hydronephrosis or non-functioning kidney
T4 IVA Tumour invades mucosa of the bladder or rectum, or extends beyond true pelvise
N – Regional Lymph Nodesf
NX Regional lymph nodes cannot be assessed
N0 No regional lymph node metastasis
N1 Regional lymph node metastasis

M – Distant Metastasisf
M0 No distant metastasis
M1 Distant metastasis (includes inguinal lymph nodes and intraperitoneal disease). It excludes
metastasis to vagina, pelvic serosa, and adnexa

a
Extension to corpus uteri should be disregarded.
b
The depth of invasion should be taken from the base of the epithelium, either surface or glandular, from which it originates. The depth of invasion is
defined as the measurement of the tumour from the epithelial–stromal junction of the adjacent most superficial papillae to the deepest point of inva-
sion. Vascular space involvement, venous or lymphatic, does not affect classification.
c
All macroscopically visible lesions even with superficial invasion are T1b/IB.
d
Vascular space involvement, venous or lymphatic, does not affect classification.
e
Bullous oedema is not sufficient to classify a tumour as T4.
f
No FIGO equivalent.
TNM, tumour, node and metastasis.
Reprinted from [61] with permission from John Wiley & Sons, Inc.

fertility [I, B] [18]. Simple hysterectomy can be offered if the invasive approach is gaining increasing relevance and is standard
patient does not wish to preserve fertility. In stage IA1 with LVSI, in most centres, since it appears to offer similar oncological safety
surgical assessment of pelvic lymph nodes should be discussed with favourable surgical morbidity [19].
with the patient, including the sentinel lymph node (SLN, see
below). Sentinel lymph node dissection in cervical cancer. SLN dissec-
In patients with FIGO stage IA2, IB and IIA, radical hysterec- tion (SLND) is standard in the treatment of breast cancer as
tomy with bilateral lymph node dissection (with or without SLN) well as vulvar cancer and increasing evidence also suggests an
is standard treatment, if the patient does not wish to preserve fer- important role for SLND in cervical cancer. While the evidence
tility [I, B]. This can be carried out either by laparotomy or lapar- is still evolving and guideline recommendations are not yet
oscopy (which can be robotically assisted). The minimally clearly defined, it should be considered in FIGO stage I

Volume 28 | Supplement 4 | August 2017 doi:10.1093/annonc/mdx220 | iv75

iv76 | Marth et al.

Clinical Practice Guidelines

Positive Pap – smear / HPV – high risk positive / suspected cervix

Colposcopy / Biopsy

CIN2 / CIN3 Invasive cervical cancer Locally advanced disease Metastatic disease

Conisation Early disease

FIGO IA1 FIGO IA2 FIGO IB2 + IIA FIGO IB2 / IIB / IIIB FIGO IVA FIGO IVB

No LVSI: simple hysterectomy CRT Chemotherapy Chemotherapy

Frozen section: conisation Radical hysterectomy Radical hysterectomy + Tailoring of radiation (C)RT + bevacizumab
only if negative margins Simple hysterectomy PLND ± PALND according to surgical Pelvic exenteration RT
Trachelectomy + SLN staging or PET-CT
With LVSI: simple PLND ± PALND Frozen section: trachelectomy
hysterectomy + PLND ± SLN CRT Neoadjuvant chemotherapy
Volume 28 | Supplement 4 | August 2017

PALND followed by surgery

Trachelectomy or RT

Adjuvant treatment Adjuvant treatment

depending on depending on
risk factors risk factors

Annals of Oncology
Figure 1. Treatment algorithm for cervical cancer.
CIN, cervical intraepithelial neoplasia; CRT, chemoradiotherapy; FIGO, Féderation Internationale de Gynécologie et d’Obstétrique; HPV, human papillomavirus; LVSI, lymphovascular space in-
vasion; PALND, para-aortic lymph node dissection; Pap, Papanicolaou; PET-CT, positron emission tomography/computed tomography; PLND, pelvic lymph node dissection; RT, radiotherapy;
SLN, sentinel lymph node.
Annals of Oncology Clinical Practice Guidelines
patients with tumours of  4 cm. Some evidence suggests that These results indicate that NACT may offer a benefit over sur-
the detection rate is highest if the tumour is < 2 cm. Tracer is gery alone in cervical cancer patients (borderline LACC, nodes
injected directly into the cervix, and blue dye, technetium positive, parametrial invasion at MRI), reducing the need for ad-
radiocolloid or fluorescent indocyanine green is used. SLND juvant RT [I, C].
should be done only in centres with enough expertise
and training. Sentinel nodes should be detected on both sides Chemoradiotherapy in locally advanced cervical cancer. CRT has
[II, B] [20]. been the standard of care for patients with bulky IB2–IVA disease
for almost two decades. The near simultaneous publication of five
Surgical therapy of the uterus. Since radiotherapy (RT) and randomised trials, three in LACC, collectively demonstrating an
surgery are equally effective in early stages, surgery should only be improvement in both disease-free survival (DFS) and OS with con-
considered in patients with earlier stages (up to FIGO IIA) with- comitant chemotherapy and RT over standard RT/hydroxyurea
out risk factors necessitating adjuvant therapy, which results in a (endorsed by the National Cancer Institute) changed clinical prac-
multimodal therapy without improvement of survival but tice worldwide [I, A] [29–33]. However, concerns were raised
increased toxicity [I, A]. about the applicability of the results in view of patient selection,
It is important to note that the currently established radical hys- protracted overall treatment time, the lack of a RT-only control
terectomy with extensive parametrial resection most likely consti- arm and the poor outcome in the control group. An individual pa-
tutes overtreatment in many patients, especially those with small tient data meta-analysis was undertaken to address these issues
and locally restricted tumours. Large randomised studies such as [34]. The authors identified 18 randomised trials with an RT-only
the SHAPE study are currently enrolling patients to compare simple control arm from 11 countries with the subsequent analysis limited
hysterectomy with radical hysterectomy in this population [21]. to 13 trials. The analysis confirmed the benefit of CRT but with a
smaller effect. The HR for OS and DFS was 0.81 and 0.78, respect-
Neoadjuvant chemotherapy to surgery. The rationale for the use ively, which translates into an absolute improvement of 6% and
of neoadjuvant chemotherapy (NACT) includes: (i) reduction of 8% in OS and DFS, respectively. The estimated absolute survival
the primary tumour size, allowing operability; (ii) eradication of benefit for CRT compared with RT alone was 10% for those with
micrometastatic disease; and (iii) potential increase in tumour FIGO stage I/II disease, compared with 3% for those with FIGO
vascularisation and reduction of the number of hypoxic cells [22–24]. stage III/IVa. The most commonly used regimen is weekly cisplatin
In a meta-analysis, NACT followed by radical surgery showed a 40 mg/m2, although the meta-analysis also reported significant
highly significant 35% reduction in the risk of death compared with benefits with non-platinum agents [I, A] [34].
RT alone [hazard ratio (HR) ¼ 0.65; P ¼ 0.0004], with an absolute More recently, colleagues in Mexico reported on a large
improvement of 14% in survival at 5 years, increasing from 50% to randomised phase III trial comparing standard CRT with a more
64% [25]. The analysis included data from 872 patients with LACC intensive concomitant approach with gemcitabine/cisplatin fol-
enrolled in five different trials. The largest trial included in a second lowed by an additional two cycles of adjuvant chemotherapy
meta-analysis, enrolled 441 FIGO stage IB2–III cervical cancer pa- [35]. Yet, despite a reported 9% improvement in progression-
tients and compared platinum-based NACT followed by radical free survival (PFS) at 3 years with treatment intensification, this
surgery with conventional RT. The main criticism of this study is approach has not been widely adopted amid concerns about tox-
related to the suboptimal RT administration; almost 27% of pa- icity [II, C]. Meanwhile two international trials of additional
tients did not receive intracavitary RT; 11% of patients received less chemotherapy delivered either before (INTERLACE) or after
than 60 Gy of external pelvic beam radiation total dose at point A CRT (OUTBACK) are ongoing and will hopefully answer the
and the median total dose delivered was 70 Gy, while the optimal question as to whether this approach will improve OS further.
treatment is considered to be 80–90 Gy at point A. Technical advances in imaging and in RT planning have facili-
Moreover, in all of these studies, the control arm, RT alone tated a move towards increased precision in brachytherapy prac-
without concomitant chemotherapy, does not represent the cur- tice. This approach has been championed by groups in Austria,
rent standard of care for LACC. In addition, the RT total dose Denmark and France with the dual aim of improving outcome
and the median time of RT administration were sometimes through dose escalation while reducing the toxicity to the sur-
suboptimal. rounding normal tissues [36]. A recently published multicentre co-
There are two randomised phase III trials that have explored the hort study (RetroEMBRACE) demonstrated excellent local control
role of NACT followed by surgery versus chemoradiotherapy (CRT), rates of 93% and 79% for patients with FIGO stage IIB and IIIB
but the results are not yet available (EORTC Protocol 55994 and disease, respectively, at 3 years [37]. However, the 5-year actuarial
NCT00193739) [26, 27]. OS was 65% and, while this is better than historical controls, it re-
Moreover, a recent meta-analysis comparing NACT followed mains to be seen whether this truly represents an improvement in
by surgery versus surgery alone confirmed that patients treated survival over standard CRT with lower RT doses. With a median
with NACT had higher local control [odds ratio (OR) ¼ 0.67; follow up of 43 months, the actuarial 5-year G3–G5 morbidity was
95% confidence interval (CI): 0.45–0.99; P ¼ 0.04)] [28]. 5%, 7% and 5% to the bladder, gastrointestinal tract and vagina,
Exploratory analysis of pathological response showed a signifi- respectively, confirming that the improved local control was
cant decrease in adverse pathological findings with NACT achieved with a low risk of morbidity [I, B]. Given the rarity of
(OR ¼ 0.54; P < 0.0001 for lymph node status; OR ¼ 0.58; small-cell neuroendocrine carcinoma, there are limited data to
P ¼ 0.002 for parametrial infiltration). However, a significant guide treatment of this type of cervical cancer. Most clinicians
percentage of patients will not have surgery because of treatment favour: the use of combined modality therapy (surgery followed by
toxicity or insufficient response. chemotherapy or combined CRT) for limited-stage potentially

Volume 28 | Supplement 4 | August 2017 doi:10.1093/annonc/mdx220 | iv77

Clinical Practice Guidelines Annals of Oncology
resectable disease; definitive CRT for locoregionally advanced Table 3. Necessary histopathological parameters for assessment of
unresectable but non-metastatic disease; and palliative chemother- cervical cancer
apy alone for those with metastatic disease, using chemotherapy
Histopathological evaluation
regimens that are typically used for small-cell lung cancer.
Dimensions of the tumour
Stromal invasion/depth of the wall involved
Neoadjuvant chemotherapy and radiotherapy. The concept of Tumour differentiation
delivering chemotherapy before RT (neoadjuvant or induction Lymphovascular space invasion
chemotherapy) has been explored in clinical trials with conflicting Status of resection margins
results. An individual patient data meta-analysis was undertaken Status of parametria and vaginal cuff
of 18 randomised trials involving over 2000 patients [38]. Number and status of lymph nodes
Heterogeneity in trial design precluded a unified analysis.
However, the authors identified cycle length and platinum dose in-
tensity as important factors in determining the impact of NACT recurrence rate alone but, when combined, the risk of recurrence is
on outcome. The trials that delivered short-cycle chemotherapy increased to 15%–20%, similar to that of high-risk factors.
( 14 days) gave a pooled HR of 0.83, equivalent to an improve-
ment of 7% in 5-year survival. In contrast, the trials with longer Intermediate-risk disease. A Gynecologic Oncology Group
chemotherapy cycles (> 14 days) gave a pooled HR of 1.25, equiva- (GOG) trial that randomly assigned 277 women to receive pelvic
lent to an absolute detriment in survival of 8% at 5 years. RT (without chemotherapy) or no further treatment demon-
Accelerated repopulation of resistant cancer cells during prolonged strated a benefit for postoperative RT in women with the follow-
intervals (up to 6 weeks in some studies) between NACT and RT ing features: deep cervical stromal invasion (to the middle or
may account for the detrimental effect seen in some studies. The one-third depth), LVSI and large tumour size (> 4 cm). With a
ongoing INTERLACE trial, which is randomising patients with median follow-up of 10 years, a significant benefit has been
LACC between standard CRT alone and 6 weeks of induction shown for PFS (HR 0.54), but not for OS (HR 0.7; P ¼ 0.07) [42].
chemotherapy followed immediately in week 7 by standard CRT,
seeks to address some of these issues by studying the use of a dose-
High-risk disease. Women with one or more negative prognostic
dense schedule, incorporating a taxane and eliminating the interval
factors such as positive or close surgical margins, positive lymph
between induction chemotherapy and RT.
nodes or microscopic parametrial involvement are considered to
be at high risk of relapse. In this setting of patients, adjuvant CRT
Lymph node staging and radiotherapy. In patients with LACC, is indicated based on a clinical trial that randomly assigned 268
RT treatment planning relies on accurate staging information. women IA2, IB and IIA to adjuvant RT with or without chemo-
Pelvic MRI and clinical examination is essential to determine the therapy (cisplatin–5-fluorouracil) for four courses [33]. The use
local extent of the tumour for both external beam RT and brachy- of chemotherapy was associated with a substantially better 4-year
therapy planning. Information on para-aortic nodal status is also OS (81% versus 71%) and PFS (80% versus 63%) and the out-
essential for treatment planning, particularly in determining the come was better for patients who completed three to four cycles
superior extent of the external beam RT portal. FIGO staging of chemotherapy [I, A].
does not take account of the nodal status and this is one of the Cervical cancer patients with intermediate-risk disease do not
weaknesses of this system. Surgical series suggest that the inci- need further adjuvant therapy [II, B], whereas adjuvant CRT is
dence of para-aortic nodal involvement increases with stage from recommended in high-risk patients [I, A].
about 5% in patients with stage I disease to 25% in those with
stage III disease [39].
There is much debate concerning the best way to assess the Management of advanced/metastatic
para-aortic nodes. In some parts of the world, PET/CT is rou-
tinely used for staging while elsewhere there is a reliance on surgi- disease (Figure 1)
cal exploration of the para-aortic region. It is hoped that the Metastatic or recurrent cervical cancer is usually a symptomatic
ongoing randomised trials will address this issue further [40]. and devastating situation for the patient. Palliative chemotherapy
This is particularly important in the light of the findings from a with the aim of relieving symptoms and improving quality of life
multicentre, randomised trial demonstrating an excellent out- is indicated if the patient has a performance status (PS)  2 and
come in patients with negative PET scans and metastasis  5 mm no formal contraindications. Cisplatin 50 mg/m2 every 3 weeks
detected histologically after surgical removal and subsequently was, for two decades, the standard of care. However, the global ef-
treated with extended-field CRT [41]. ficacy was disappointing due to a low response rate (20%), short
median PFS (2.8–3.2 months) and OS (6.2–8.0 months).
Cisplatin-based doublets with topotecan or paclitaxel have
Adjuvant treatment demonstrated superiority to cisplatin monotherapy in terms of
Women with risk factors on the pathology specimen should re- response rate and PFS [43, 44]. Cisplatin combined with topote-
ceive adjuvant therapy following hysterectomy (Table 3). Two can showed superior OS compared with cisplatin alone. Both tri-
classes of risk are defined: intermediate- and high-risk patients. als also demonstrated that the response rate was clearly inferior in
However, intermediate-risk factors such as LVSI, large tumour size patients previously exposed to CRT. In addition, retrospective
and deep stromal invasion (DSI) do not significantly increase the pooled analysis suggested that black race, pelvic location rather

iv78 | Marth et al. Volume 28 | Supplement 4 | August 2017

Annals of Oncology Clinical Practice Guidelines
than non-pelvic, PS 1 or 2 and first relapse within 1 year of diag-
Table 4. Second-line therapy for metastatic cervical cancer
nosis may also be poor prognostic factors associated with lower
response [45]. Agent N CR1PR PFS OS
The three-drug combination of paclitaxel–ifosfamide–cisplatin (%) (months) (months)
(TIP) has shown promising responses (overall response rate 62%,
Bevacizumab [48] 46 11 3.4 7.3
with complete response 26%) and is regarded as an active regimen
Topotecan [62, 63] 94 13-19 2.1-2.4 6.4-6.6
with acceptable toxicity in advanced/relapsed cervical cancer [46].
Vinorelbine [64] 44 14 - -
A large randomised phase III trial (GOG-204) comparing four Gemcitabine [65] 22 5 2.1 6.5
different cisplatin-based doublets with paclitaxel, topotecan, gem- Albumin-bound paclitaxel [66] 35 29 5.0 9.4
citabine or vinorelbine was unable to demonstrate the superiority Docetaxel [67] 23 9 3.8 7.0
of any regimen. Nevertheless, paclitaxel–cisplatin showed the high- Pemetrexed [68, 69] 72 14-15 2.5-3.1 7.4-8.8
est response rate (29%), median PFS (5.8 months) and median OS Irinotecan [70] 42 21 4.5 6.4
(12.8 months) and was considered the preferred regimen based on Sunitinib [71] 19 0 3.5 -
the balance between efficacy and toxicity profile [II, B] [47]. Erlotinib [72] 28 0 1.9 5.0
Tumour angiogenesis plays a significant role in the progression Lapatinib [73] 78 5 4.2 9.7
of cervical cancer and has been associated with a poor prognosis. Pazopanib [73] 74 9 4.5 12.7
Bevacizumab prevents tumour angiogenesis by blocking vascular Pegylated liposomal 27 11 3.2 8.9
endothelial growth factor and was shown to be active in a phase II doxorubicin [74]
study (GOG-227C) in recurrent cervical cancer [48]. Based on
this observation, the GOG-240 study explored the addition of CR, complete response; OS, overall survival; PFS, progression-free sur-
bevacizumab to chemotherapy in a randomised phase III trial vival; PR, partial response.
with a 2 2 factorial design in which OS was the primary end-
point. Patients with primary stage IVB or recurrent/persistent,
good PS (0 or 1) and measurable disease were randomised to RT can play an important role in patients with recurrent dis-
paclitaxel–cisplatin or paclitaxel–topotecan, both with or with- ease, in the case of oligometastatic disease and for patients with
out bevacizumab. Two main conclusions were obtained from this only nodal metastasis in the pelvic, periaortic and/or supraclavic-
study: first, the median OS is significantly prolonged by the add- ular regions, as high-dose RT often leads to long-term disease
ition of bevacizumab (16.8 versus 13.3 months; HR 0.765; 95% control and a prolonged progression-free interval. Short-course
CI: 0.62–0.95; P ¼ 0.0068) and second, non-platinum doublet is palliative RT is used to treat symptoms from distant metastases.
not superior to cisplatin–paclitaxel, even in the population previ-
ously treated with cisplatin. Patients treated with bevacizumab
had a higher risk of grade  2 hypertension (25% versus 1.8%), Local recurrence of cervical cancer following
grade  3 venous thromboembolic events (8.2% versus 1.8%) radical surgery
and grade  2 fistula (8.6% versus 1%), and these side-effects The therapeutic options for patients who relapse in the pelvis fol-
must be carefully monitored during treatment [49]. lowing primary surgery are either radical RT or pelvic exentera-
The combination of paclitaxel and carboplatin could be con- tion. The reported survival rates range from 6% to 77%; patients
sidered an alternative for patients that are not candidates for cis- with central recurrences have better prognoses than those with
platin. Although a Japanese randomised clinical trial which pelvic side wall recurrence. Patients with central recurrences had
compared the two regimens showed a similar efficacy, the com- a 10-year survival rate of 77%, for those with no palpable tumour,
bination with cisplatin was superior to carboplatin in patients and a 10-year survival rate of 48% if the recurrence was < 3 cm;
without previous exposure to cisplatin [50]. The combination of there were no long-term survivors among patients with bulky
carboplatin/paclitaxel/bevacizumab is being studied in a multi- (> 3 cm) central recurrence in one series. The major prognostic
centre, single-arm, interventional trial (CECILIA), to evaluate factors associated with survival following salvage radiation in
the safety and efficacy of the combination in recurrent and/or patients with recurrent pelvic disease include disease-free inter-
metastatic cervical cancer (NCT02467907). val, site of recurrence (i.e. central versus pelvic side wall), and
Paclitaxel and cisplatin combined with bevacizumab is con- size. Higher doses of RT can be delivered with brachytherapy and
sidered the preferred first-line regimen in metastatic or recurrent increase the likelihood of local control for patients with small vol-
cervical cancer based on the balance between efficacy and toxicity ume central recurrences. Patients with large volume central or
profile [I, A]. pelvic side wall recurrences have poor prognoses, and efforts
In patients progressing following first-line therapy, different should be made to detect pelvic recurrences early to increase the
cytostatic agents, including vinorelbine, topotecan, gemcitabine chance of long-term survival [51].
or nanoparticle albumin-bound paclitaxel have been evaluated
(Table 4). However, response rates are low and duration of re-
sponses is short. Therefore, no recommendation can be given Fertility sparing
about the most effective second-line treatment (Table 4). More than 40% of women with early cervical cancer are affected
Some patients develop small lung metastases only, which do during reproductive age and wish to remain fertile. Thus, many
not rapidly progress and can be managed with stereotactic RT patients demand a more conservative policy for managing these
and/or a watchful waiting policy, frequently delaying systemic lesions in order to increase the chance of having an uneventful
chemotherapy for a significant period of time. pregnancy in the future.

Volume 28 | Supplement 4 | August 2017 doi:10.1093/annonc/mdx220 | iv79

Clinical Practice Guidelines Annals of Oncology
Table 5. Summary of recommendations
Incidence and epidemiology
 Primary prevention of cervical cancer is now possible via immunisation with highly efficacious HPV vaccines [II, A] and secondary prevention has gained
impetus with the advent of sensitive HPV DNA testing to improve traditional Pap cytology screening programs [II, A].
Staging and risk assessment
 Tumour risk assessment includes tumour size, stage, depth of tumour invasion, lymph node status, LVSI and histological subtype. Lymph node status and
number of lymph nodes involved are the most important prognostic factors.
Management of local/locoregional disease
Surgery
 Surgical therapy in cervical cancer is adapted to the stage of disease according to FIGO and TNM classification (see Table 2).
 Microinvasive cervical cancer (stage IA1) without LVSI can be managed with conisation or simple trachelectomy to preserve fertility [I, B]. Simple hysterec-
tomy can be offered if the patient does not wish to preserve fertility.
 In stage IA1 with LVSI, surgical assessment of pelvic lymph nodes should be discussed with the patient, including the SLN.
 In patients with FIGO stage IA2, IB and IIA, radical hysterectomy with bilateral lymph node dissection (with or without SLN) is standard treatment, if the
patient does not wish to preserve fertility [I, B].
 Increasing evidence suggests an important role for SLND in cervical cancer. Sentinel nodes should be detected on both sides [II, B].
 Surgery should only be considered in patients with earlier stages of cervical cancer (up to FIGO IIA) without risk factors necessitating adjuvant therapy,
which results in a multimodal therapy without improvement of survival but increased toxicity [I, A].
 Study results indicate that NACT may offer a benefit over surgery alone in cervical cancer patients, reducing the need for adjuvant RT [I, C].
Chemoradiotherapy in locally advanced cervical cancer
 CRT has been the standard of care for patients with bulky IB2–IVA disease for almost two decades, demonstrating an improvement in both DFS and OS
with concomitant chemotherapy and RT over standard RT/hydroxyurea [I, A].
 The most commonly used regimen is weekly cisplatin 40 mg/m2, although the meta-analysis also reported significant benefits with non-platinum agents
[I, A].
Adjuvant treatment
 Women with intermediate- and high-risk factors on the pathology specimen should receive adjuvant therapy following hysterectomy (see Table 3).
 Cervical cancer patients with intermediate-risk disease do not need further adjuvant therapy [II, B], whereas adjuvant CRT is recommended in high-risk
patients [I, A].
Management of advanced/metastatic disease
 Palliative chemotherapy with the aim of relieving symptoms and improving quality of life is indicated if the patient has a PS < 2 and no formal
contraindications.
 Cisplatin-based doublets with topotecan or paclitaxel have demonstrated superiority to cisplatin monotherapy in terms of response rate and PFS.
 Paclitaxel and cisplatin combined with bevacizumab is considered the preferred first-line regimen in metastatic or recurrent cervical cancer based on the
balance between efficacy and toxicity profile [I, A].
 The combination of paclitaxel and carboplatin could be considered an alternative for patients that are not candidates for cisplatin.
 For FIGO Stage IA1 patients, conisation is recommended as a first diagnostic and curative step for microscopic tumours in the presence of negative mar-
gins and the absence of clinical contraindications to surgery. PLND is recommended for patients with LVSI, who have an increased risk of lymph node in-
volvement. Sentinel node biopsy or trachelectomy [II, B] should be considered in some patients.
 For FIGO Stage IA2 patients wishing to preserve fertility, cone biopsy or radical trachelectomy with PLND is the standard procedure.
 Scientific evidence shows that trachelectomy with pelvic lymphadenectomy is the most appropriate surgical treatment of fertility sparing in patients
with tumours measuring  2 cm in diameter (FIGO Stage IB1 < 2 cm) [II, B]. For tumours > 2 cm, NACT followed by conisation or trachelectomy may
also be a valid choice.
Follow-up, long-term implications and survivorship
 Follow-up visits with a complete physical examination including a pelvic–rectal exam and a patient history should be conducted by a physician experi-
enced in the surveillance of cancer patients.
 CT or PET/CT scan should be carried out as clinically indicated. A reasonable follow-up schedule involves follow-up visits every 3–6 months in the first
2 years and every 6–12 months in years 3–5.
 Patients should return to annual population-based general physical and pelvic examinations after 5 years of recurrence-free follow-up [III, C].

CRT, chemoradiotherapy; CT, computed tomography; DFS, disease-free survival; DNA, deoxyribonucleic acid; FIGO, Féderation Internationale de
Gynécologie et d’Obstétrique; HPV, human papillomavirus; LVSI, lymphovascular space invasion; NACT, neoadjuvant chemotherapy; OS, overall sur-
vival; Pap, Papanicolaou; PET/CT, positron emission tomography/computed tomography; PFS, progression-free survival; PLND, pelvic lymph node
dissection; PS, performance status; RT, radiotherapy; SLN, sentinel lymph node; SLND, sentinel lymph node dissection; TNM, tumour, node and
metastasis.

FIGO stage IA1 the presence of negative margins and the absence of clinical
contraindications to surgery, the cone biopsy may represent de-
According to most international guidelines, the first diagnostic
finitive treatment. For patients with LVSI, who have an increased
and curative step for microscopic tumours is conisation [52]. In

iv80 | Marth et al. Volume 28 | Supplement 4 | August 2017

Annals of Oncology Clinical Practice Guidelines
Table 6. Levels of evidence and grades of recommendation (adapted from that less radical treatment may be a valid choice for fertility sparing
the Infectious Diseases Society of America-United States Public Health also in these lesions (lower morbidity, higher pregnancy rate).
Service Grading Systema) Some studies have reported in the absence of residual disease in
trachelectomy specimens in the range of 60%–65%, questioning
Levels of evidence
the need for radical surgery in patients with low-risk tumours [56].
I Evidence from at least one large randomised, controlled trial of
good methodological quality (low potential for bias) or meta-
Finally, some authors have suggested conisation with/without
analyses of well-conducted randomised trials without
NACT in this tumour setting as well [II, C] [55, 57–60].
heterogeneity
II Small randomised trials or large randomised trials with a suspicion FIGO stage IB > 2 cm
of bias (lower methodological quality) or meta-analyses of such
For tumours > 2 cm, NACT followed by conisation or trachelec-
trials or of trials with demonstrated heterogeneity
tomy may also be a valid choice, but downstaging by NACT in
III Prospective cohort studies
IB1 and IB2 cervical cancer before fertility-sparing surgery is still
IV Retrospective cohort studies or case–control studies
an experimental procedure [I, C].
V Studies without control group, case reports, experts opinions

Grades of recommendation
A Strong evidence for efficacy with a substantial clinical benefit, Personalised medicine
strongly recommended
B Strong or moderate evidence for efficacy but with a limited clin- In this disease setting, more research is needed to identify molecular
ical benefit, generally recommended markers which could lead to advances in personalised medicine.
C Insufficient evidence for efficacy or benefit does not outweigh
the risk or the disadvantages (adverse events, costs, . . . ).,
optional Follow-up, long-term implications and
D Moderate evidence against efficacy or for adverse outcome, gen-
erally not recommended
survivorship
E Strong evidence against efficacy or for adverse outcome, never No definitive agreement exists on the best post-treatment surveil-
recommended lance of cervical cancer. At a minimum, follow-up visits with a
a
complete physical examination, including a pelvic–rectal exam
By permission of the Infectious Diseases Society of America [75].
and a patient history, should be conducted by a physician experi-
enced in the surveillance of cancer patients. There is little evidence
to suggest that vaginal vault cytology adds significantly to the clin-
risk of lymph node involvement, pelvic lymph node dissection ical exam in detecting early disease recurrence. Routine use of vari-
(PLND) is recommended [52]. Sentinel node biopsy should be ous other radiological or biological follow-up investigations in
considered. Moreover, for these patients, some authors suggest asymptomatic patients is not advocated, because the role of those
trachelectomy, a surgical procedure in which the uterine cervix investigations has yet to be evaluated in a definitive manner. CT or
and adjacent tissues are removed [II, B]. PET/CT scan should be carried out as clinically indicated. A reason-
able follow-up schedule involves follow-up visits every 3–6 months
in the first 2 years and every 6–12 months in years 3–5. Patients
FIGO stage IA2 should return to annual population-based general physical and pel-
vic examinations after 5 years of recurrence-free follow-up [III, C].
For patients wishing to preserve fertility, cone biopsy or radical
trachelectomy with PLND is the standard procedure [53].
Sentinel node biopsy is under validation but may be considered
[II, B]. Methodology
These Clinical Practice Guidelines were developed in accordance
with the ESMO standard operating procedures for Clinical Practice
FIGO stage IB1 < 2 cm Guidelines development http://www.esmo.org/Guidelines/ESMO-
Scientific evidence shows that trachelectomy with pelvic lympha- Guidelines-Methodology. The relevant literature has been selected
denectomy is the most appropriate surgical treatment of fertility by the expert authors. A summary of recommendations is shown in
sparing in patients with these tumours. Tumours > 2 cm are Table 5. Levels of evidence and grades of recommendation have
clearly associated with a higher risk of recurrence (3% for le- been applied using the system shown in Table 6. Statements without
sions  2 cm versus 17% for lesions > 2 cm); thus, international grading were considered justified standard clinical practice by the
guidelines stress that this procedure is valid mostly for tumours experts and the ESMO Faculty. This manuscript has been subjected
measuring  2 cm in diameter [II, B] [54, 55]. to an anonymous peer review process.
Currently, as documented by most international guidelines, rad-
ical trachelectomy is considered a standard fertility-sparing proced-
ure in patients with early cervical cancer and tumours < 2 cm. Disclosure
However, the low incidence of parametrial involvement reported in CM and MMC have reported honoraria and participation at
patients with tumours < 2 cm and no nodal disease or LVSI suggest advisory boards for Roche; SM has reported consulting for

Volume 28 | Supplement 4 | August 2017 doi:10.1093/annonc/mdx220 | iv81

Clinical Practice Guidelines Annals of Oncology
Roche, Clovis, Sensor Kinesis, MEDAC, AstraZeneca and has 20. Diab Y. Sentinel lymph nodes mapping in cervical cancer a comprehen-
received grants from Roche, Pharmamar, Tesaro, MEDAC, sive review. Int J Gynecol Cancer 2017; 27: 154–158.
21. Canadian Cancer Trials Group. Radical versus simple hysterectomy and
AstraZeneca and honoraria from Roche, Pharmamar, Clovis,
pelvic node dissection in patients with low-risk early stage cervical cancer
Tesaro, Sensor Kinesis, MEDAC and AstraZeneca; AGM has (SHAPE). https://clinicaltrials.gov/ct2/show/NCT01658930 (29 April
received honoraria from Roche, AstraZeneca and PharmaMar; 2017, date last accessed).
NC is a member of Roche speakers’ bureau; FL has reported no 22. Benedetti-Panici P, Greggi S, Scambia G et al. Long-term survival follow-
conflict of interest. ing neoadjuvant chemotherapy and radical surgery in locally advanced
cervical cancer. Eur J Cancer 1998; 34: 341–346.
23. Sardi JE, di Paola GR, Cachau A et al. A possible new trend in the man-
agement of the carcinoma of the cervix uteri. Gynecol Oncol 1986; 25:
References 139–149.
1. Torre LA, Bray F, Siegel RL et al. Global cancer statistics, 2012. CA 24. Paladini D, Raspagliesi F, Fontanelli R, Ntousias V. Radical surgery after
Cancer J Clin 2015; 65: 87–108. induction chemotherapy in locally advanced cervical cancer. A Feasibility
2. International Agency for Research on Cancer, EUCAN. http://eco.iarc.fr/ Study. Int J Gynecol Cancer 1995; 5: 296–300.
eucan (29 April 2017, date last accessed). 25. Neoadjuvant Chemotherapy for Locally Advanced Cervical Cancer
3. Sant M, Chirlaque Lopez MD, Agresti R et al. Survival of women with Meta-analysis Collaboration. Neoadjuvant chemotherapy for locally
cancers of breast and genital organs in Europe 1999–2007: results of the advanced cervical cancer: a systematic review and meta-analysis of indi-
EUROCARE-5 study. Eur J Cancer 2015; 51: 2191–2205. vidual patient data from 21 randomised trials. Eur J Cancer 2003; 39:
4. Petrosky E, Bocchini JA Jr, Hairi S et al. Use of 9-valent human papillo- 2470–2486.
mavirus (HPV) vaccine: updated HPV vaccination recommendations of 26. European Organisation for Research and Treatment of Cancer – EORTC.
the Advisory Committee on Immunization Practices. MMWR Morb Chemotherapy followed by surgery vs radiotherapy plus chemotherapy in
Mortal Wkly Rep 2015; 64: 300–304. patients with stage Ib or II cervical cancer. EORTC Protocol 55994. https://
5. FUTURE II Study Group. Quadrivalent vaccine against human papillo- clinicaltrials.gov/ct2/show/NCT00039338 (29 April 2017, date last accessed).
mavirus to prevent high grade cervical lesion. N Engl J Med 2007; 356: 27. Gupta S. Neoadjuvant chemotherapy followed by surgery versus concur-
1915–1927. rent chemoradiation in carcinoma of the cervix (NACTcervix).
6. Paavonen J, Naud P, Salmer on J et al. Efficacy of human papillomavirus NCT00193739. https://clinicaltrials.gov/ct2/show/NCT00193739
(HPV) 16/18 AS04-adjuvanted vaccine against cervical infection and precancer NCT00193739 https://clinicaltrials.gov/ct2/show/NCT00193739 (29
caused by oncogenic HPV types (PATRICIA): final analysis of a double-blind, April 2017, date last accessed).
randomised study in young women. Lancet 2009; 374: 301–314. 28. Rydzewska L, Tierney J, Vale CL, Symonds PR. Neoadjuvant chemother-
7. Joura EA, Giuliano AR, Iversen OE et al. A 9-valent HPV vaccine against apy plus surgery versus surgery for cervical cancer. Cochrane Database
infection and intraepithelial neoplasia in women. N Engl J Med 2015; Syst Rev 2012; 12: CD007406.
372: 711–723. 29. Whitney CW, Sause W, Bundy BN et al. Randomized comparison of flu-
8. Markowitz LE, Liu G, Hariri S et al. Prevalence of HPV after introduc- orouracil plus cisplatin versus hydroxyurea as an adjunct to radiation
tion of the vaccination program in the United States. Pediatrics 2016; therapy in stage IIB–IVA carcinoma of the cervix with negative para-
137: e20151968. aortic lymph nodes: a Gynecologic Oncology Group and Southwest
9. Ali H, Donovan B, Wand H et al. Genital warts in young Australians five Oncology Group study. J Clin Oncol 1999; 17: 1339–1348.
years into national human papillomavirus vaccination programme: na- 30. Rose PG, Bundy BN, Watkins EB et al. Concurrent cisplatin-based radio-
tional surveillance data. BMJ 2013; 346: f2032. therapy and chemotherapy for locally advanced cervical cancer. N Engl J
10. Ronco G, Dillner J, Elfström KM et al. Efficacy of HPV-based screening Med 1999; 340: 1144–1153.
for prevention of invasive cervical cancer: follow-up of four European 31. Morris M, Eifel PJ, Lu J et al. Pelvic radiation with concurrent chemo-
randomised controlled trials. Lancet 2014; 383: 524–532. therapy compared with pelvic and para-aortic radiation for high-risk cer-
11. Serrano B, de Sanjosé S, Tous S et al. Human papillomavirus genotype vical cancer. N Engl J Med 1999; 340: 1137–1143.
attribution for HPVs 6, 11, 16, 18, 31, 33, 45, 52 and 58 in female ano- 32. Keys HM, Bundy BN, Stehman FB et al. Cisplatin, radiation, and adjuvant
genital lesions. Eur J Cancer 2015; 51: 1732–1741. hysterectomy compared with radiation and adjuvant hysterectomy for
12. Alemany L, Cubilla A, Halec G et al. Role of human papillomavirus in bulky stage IB cervical carcinoma. N Engl J Med 1999; 340: 1154–1161.
penile carcinomas worldwide. Eur Urol 2016; 69: 953–961. 33. Peters WA, 3rd, Liu PY, Barrett RJ, 2nd et al. Concurrent chemotherapy
13. Alemany L, Saunier M, Alvarado-Cabrero I et al. Human papillomavirus and pelvic radiation therapy compared with pelvic radiation therapy
DNA prevalence and type distribution in anal carcinomas worldwide. Int alone as adjuvant therapy after radical surgery in high-risk early-stage
J Cancer 2015; 136: 98–107. cancer of the cervix. J Clin Oncol 2000; 18: 1606–1613.
14. Wagenaar HC, Trimos JB, Postema S et al. Tumor diameter and volume 34. Chemoradiotherapy for Cervical Cancer Meta-Analysis
assessed by magnetic resonance imaging in the prediction of outcome for Collaboration. Reducing uncertainties about the effects of chemora-
invasive cervical cancer. Gynecol Oncol 2001; 82: 474–482. diotherapy for cervical cancer: a systematic review and meta-analysis
15. Patel CN, Nazir SA, Khan Z et al. 18F-FDG PET/CT of cervical carcin- of individual patient data from 18 randomized trials. J Clin Oncol
oma. AJR Am J Roentgenol 2011; 196: 1225–1233. 2008; 26: 5802–5812.
16. Brockbank E, Kokka F, Bryant A et al. Pre-treatment surgical para-aortic 35. Due~ nas-Gonzalez A, Zarba JJ, Patel F et al. Phase III, open-label,
lymph node assessment in locally advanced cervical cancer. Cochrane randomized study comparing concurrent gemcitabine plus cisplatin and
Database Syst Rev 2011; 4: CD008217. radiation followed by adjuvant gemcitabine and cisplatin versus concur-
17. Kim SM, Choi HS, Byun JS. Overall 5-year survival rate and prognostic rent cisplatin and radiation in patients with stage IIB to IVA carcinoma
factors in patients with stage IB and IIA cervical cancer treated by radical of the cervix. J Clin Oncol 2011; 29: 1678–1685.
hysterectomy and pelvic lymph node dissection. Int J Gynecol Cancer 36. Tanderup K, Lindegaard JC, Kirisits C et al. Image guided adaptive
2000; 10: 305–312. brachytherapy in cervix cancer: a new paradigm changing clinical prac-
18. Dittrich R, Lotz L, Hackl J et al. Fertilit€atserhalt bei Krebserkrankungen. tice and outcome. Radiother Oncol 2016; 120: 365–369.
Frauenarzt 2014; 55: 240–246. 37. Sturdza A, Pötter R, Fokdal LU et al. Image guided brachytherapy in lo-
19. Geetha P, Nair MK. Laparoscopic, robotic and open method of radical cally advanced cervical cancer: improved pelvic control and survival in
hysterectomy for cervical cancer: a systematic review. J Min Access Surg RetroEMBRACE, a multicenter cohort study. Radiother Oncol 2016;
2012; 8: 67–73. 120: 428–433.

iv82 | Marth et al. Volume 28 | Supplement 4 | August 2017

Annals of Oncology Clinical Practice Guidelines
38. Neoadjuvant Chemotherapy for Cervical Cancer Meta-analysis Collaboration 57. Maneo A, Sideri M, Scambia G et al. Simple conization and lymphade-
(NACCCMA). Neoadjuvant chemotherapy for locally advanced cervix can- nectomy for the conservative treatment of stage IB1 cervical cancer. An
cer. Cochrane Database Syst Rev 2004; 2: CD001774. Italian experience. Gynecol Oncol 2011; 123: 557–560.
39. Berman ML, Keys H, Creasman W et al. Survival and patterns of 58. Fagotti A, Gagliardi ML, Moruzzi C et al. Excisional cone as fertility-
recurrence in cervical cancer metastatic to periaortic lymph nodes sparing treatment in early-stage cervical cancer. Fertil Steril 2011; 95:
(a Gynecologic Oncology Group study). Gynecol Oncol 1984; 19: 8–16. 1109–1112.
40. Indonesia University. 10 vs 14 Days Triple Therapy: H. pylori Infection 59. Fanfani F, Landoni F, Gagliardi ML et al. Sexual and reproductive outcomes
Eradication. NCT01566240. https://clinicaltrials.gov/ct2/show/ (29 April in early stage cervical cancer patients after excisional cone as a fertility-
2017, date last accessed). sparing surgery: an Italian experience. J Reprod Infertil 2014; 15: 29–34.
41. Gouy S, Morice P, Narducci F et al. Prospective multicenter study evalu- 60. Choi MC, Jung SG, Park H et al. Photodynamic therapy for management
ating the survival of patients with locally advanced cervical cancer of cervical intraepithelial neoplasia II and III in young patients and ob-
undergoing laparoscopic para-aortic lymphadenectomy before chemora- stetric outcomes. Lasers Surg Med 2013; 45: 564–572.
diotherapy in the era of positron emission tomography imaging. J Clin 61. James D, Brierley JD, Gospodarowicz MK et al. (eds). TNM Classification of
Oncol 2013; 31: 3026–3033. Malignant Tumours, 8th edition. Oxford, UK: John Wiley & Sons, Inc. 2016.
42. Rotman M, Sedlis A, Piedmonte MR et al. A phase III randomized trial 62. Bookman MA, Blessing JA, Hanjani P et al. Topotecan in squamous cell
of postoperative pelvic irradiation in Stage IB cervical carcinoma with carcinoma of the cervix: a phase II study of the Gynecologic Oncology
poor prognostic features: follow-up of a Gynecologic Oncology Group Group. Gynecol Oncol 2000; 77: 446–449.
study. Int J Radiat Oncol Biol Phys 2006; 65: 169–176. 63. Muderspach LI, Blessing JA, Levenback C, Moore JL Jr. A phase II study
43. Moore DH, Blessing JA, McQuellon RP et al. Phase III study of cisplatin of topotecan in patients with squamous cell carcinoma of the cervix: a
with or without paclitaxel in stage IVB, recurrent, or persistent squamous Gynecologic Oncology Group study. Gynecol Oncol 2001; 81: 213–215.
cell carcinoma of the cervix: a Gynecologic Oncology Group Study. 64. Muggia FM. Relevance of chemotherapy dose and schedule to outcomes
J Clin Oncol 2004; 22: 3113–3119. in ovarian cancer. Semin Oncol 2004; 31(6 Suppl 15): 19–24.
44. Long HJ 3rd, Bundy BN, Grendys EC Jr et al. Randomized phase III 65. Schilder RJ, Blessing J, Cohn DE. Evaluation of gemcitabine in previously
trial of cisplatin with or without topotecan in carcinoma of the uterine treated patients with non-squamous cell carcinoma of the cervix: a phase
cervix: a Gynecologic Oncology Group Study. J Clin Oncol 2005; 23: II study of the Gynecologic Oncology Group. Gynecol Oncol 2005; 96:
4626–4633. 103–107.
45. Moore DH, Tian C, Monk BJ et al. Prognostic factors for response to 66. Alberts DS, Blessing JA, Landrum LM et al. Phase II trial of nab-
cisplatin-based chemotherapy in advanced cervical carcinoma: a paclitaxel in the treatment of recurrent or persistent advanced cervix
Gynecologic Oncology Group Study. Gynecol Oncol 2010; 116: 44–49. cancer: a Gynecologic Oncology Group study. Gynecol Oncol 2012;
46. Kosmas C, Mylonakis N, Tsakonas G et al. Evaluation of the paclitaxel– 127: 451–455.
ifosfamide–cisplatin (TIP) combination in relapsed and/or metastatic 67. Garcia AA, Blessing JA, Vaccarello L et al. Phase II clinical trial of doce-
cervical cancer. Br J Cancer 2009; 101: 1059–1065. taxel in refractory squamous cell carcinoma of the cervix: a Gynecologic
47. Monk BJ, Sill MW, McMeekin DS et al. Phase III trial of four cisplatin- Oncology Group Study. Am J Clin Oncol 2007; 30: 428–431.
containing doublet combinations in stage IVB, recurrent, or persistent 68. Miller DS, Blessing JA, Krasner CN et al. Phase II evaluation of peme-
cervical carcinoma: a Gynecologic Oncology Group study. J Clin Oncol trexed in the treatment of recurrent or persistent platinum-resistant
2009; 27: 4649–4655. ovarian or primary peritoneal carcinoma: a study of the Gynecologic
48. Monk BJ, Sill MW, Burger RA et al. Phase II trial of bevacizumab in the Oncology Group. J Clin Oncol 2009; 27: 2686–2691.
treatment of persistent or recurrent squamous cell carcinoma of the cervix: 69. Lorusso D, Ferrandina G, Pignata S et al. Evaluation of pemetrexed
a Gynecologic Oncology Group study. J Clin Oncol 2009; 27: 1069–1074. (Alimta, LY231514) as second-line chemotherapy in persistent or recurrent
49. Tewari KS, Sill MW, Long HJ 3rd et al. Improved survival with bevacizu- carcinoma of the cervix: the CERVIX 1 study of the MITO (Multicentre
mab in advanced cervical cancer. N Engl J Med 2014; 370: 734–743. Italian Trials in Ovarian Cancer and Gynecologic Malignancies) Group.
50. Kitagawa R, Katsumata N, Shibata T et al. Paclitaxel plus carboplatin versus Ann Oncol 2010; 21: 61–66.
paclitaxel plus cisplatin in metastatic or recurrent cervical cancer: the open- 70. Verschraegen CF, Levy T, Kudelka AP et al. Phase II study of irinotecan
label randomized phase III trial JCOG0505. J Clin Oncol 2015; 33: 2129–2135. in prior chemotherapy-treated squamous cell carcinoma of the cervix. J
51. Friedlander M, Grogan M; U.S. Preventative Services Task Force. Clin Oncol 1997; 15: 625–631.
Guidelines for the treatment of recurrent and metastatic cervical cancer. 71. Mackay HJ, Tinker A, Winquist E et al. A phase II study of sunitinib in
Oncologist 2002; 7: 342–347. patients with locally advanced or metastatic cervical carcinoma: NCIC
52. Yoneda JY, Braganca JF, Sarian LO et al. Surgical treatment of microin- CTG Trial IND.184. Gynecol Oncol 2010; 116: 163–167.
vasive cervical cancer: analysis of pathologic features with implications 72. Schilder RJ, Sill MW, Lee YC, Mannel R. A phase II trial of erlotinib in
on radicality. Int J Gynecol Cancer 2015; 25: 694–698. recurrent squamous cell carcinoma of the cervix: a Gynecologic
53. NCCN Guidelines for treatment of cervical cancer. https://www.nccn. Oncology Group Study. Int J Gynecol Cancer 2009; 19: 929–933.
org/professionals/physician_gls/pdf/cervical.pdf (15 May 2017, date last 73. Monk BJ, Mas Lopez L, Zarba JJ et al. Phase II, open-label study of pazo-
accessed). panib or lapatinib monotherapy compared with pazopanib plus lapatinib
54. Lanowska M, Mangler M, Spek A et al. Radical vaginal trachelectomy combination therapy in patients with advanced and recurrent cervical
(RVT) combined with laparoscopic lymphadenectomy: prospective cancer. J Clin Oncol 2010; 28: 3562–3569.
study of 225 patients with early-stage cervical cancer. Int J Gynecol 74. Rose PG, Blessing JA, Lele S et al. Evaluation of pegylated liposomal dox-
Cancer 2011; 21: 1458–1464. orubicin (Doxil) as second-line chemotherapy of squamous cell carci-
55. Landoni F, Parma G, Peiretti M et al. Chemo-conization in early cervical noma of the cervix: a phase II study of the Gynecologic Oncology Group.
cancer. Gynecol Oncol 2007; 107(Suppl 1): S125–S126. Gynecol Oncol 2006; 102: 210–213.
56. Plante M, Gregoire J, Renaud MC et al. Simple vaginal trachelectomy in 75. Dykewicz CA. Summary of the guidelines for preventing opportunistic
early-stage low-risk cervical cancer: a pilot study of 16 cases and review infections among hematopoietic stem cell transplant recipients. Clin
of the literature. Int J Gynecol Cancer 2013; 23: 916–922. Infect Dis 2001; 33: 139–144.

Volume 28 | Supplement 4 | August 2017 doi:10.1093/annonc/mdx220 | iv83

 Update
Annals of Oncology
Volume 29, Issue S4, October 2018, Page iv262

DOI: https://doi.org/10.1093/annonc/mdy160
 Annals of Oncology 29 (Supplement 4): iv262, 2018
doi:10.1093/annonc/mdy160
Published online 5 May 2018

CORRIGENDUM

Cervical cancer: ESMO Clinical Practice Guidelines for

diagnosis, treatment and follow-up

C. Marth, F. Landoni, S. Mahner, M. McCormack, A. Gonzalez-Martin & N. Colombo, on behalf of the

ESMO Guidelines Committee

Ann Oncol 2017; 28: iv72–iv83 (doi:10.1093/annonc/mdx220)

Under the section “Adjuvant treatment”
Adjuvant treatment
Women with risk factors on the pathology specimen should receive adjuvant therapy following hysterectomy (Table 3). Two classes of
risk are defined: intermediate- and high-risk patients.
Is replaced with:
Adjuvant treatment (Table 3)
Two classes of risk are defined: intermediate- and high-risk patients.

In “Table 5. Summary of recommendations”

Adjuvant treatment
• Women with intermediate- and high-risk factors on the pathology specimen should receive adjuvant therapy following hysterec-
tomy (see Table 3).
• Cervical cancer patients with intermediate-risk disease do not need further adjuvant therapy [II, B], whereas adjuvant CRT is rec-
ommended in high-risk patients [I, A].
Is replaced with:
Adjuvant treatment
• Cervical cancer patients with intermediate-risk disease do not need further adjuvant therapy [II, B], whereas adjuvant CRT is rec-
ommended in high-risk patients [I, A].

C The Author(s) 2018. Published by Oxford University Press on behalf of the European Society for Medical Oncology.
V
All rights reserved. For permissions, please email: journals.permissions@oup.com.